News | April 27, 2009

BSGI Identifies Cancers Mammography Missed

April 27, 2009 - An additional breast cancer was found in 9 percent of patients when breast-specific gamma imaging (BSGI) was used to complement mammography, according to a study from Beth Israel Medical Center, New York, presented at the American Society of Breast Surgeons 2009 Annual Meeting in San Diego.

The study found that of a total of 82 patients who underwent BSGI for newly diagnosed breast cancer, 18 had an additional abnormality, and 17 were biopsied.

BSGI, a molecular breast imaging technique, is an adjunct to mammography that can see lesions independent of tissue density and discover early stage cancers. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as "dark spots" on the BSGI image. The Dilon 6800 Gamma Camera is a high-resolution, compact gamma camera, optimized to perform BSGI.

"We wanted to determine the number of patients with known breast cancer who were found to have an additional lesion detected by BSGI, but undetected by mammography," said Susan K. Boolbol, M.D., chief of breast surgery at Beth Israel Medical Center, New York. "In our study group, 22 percent of patients had a change in surgical management based on BSGI findings. This is critical information in our desire to diagnose breast cancer early for successful treatment."

BSGI provides the capability of helping differentiate cancer from other structures or benign tissue in the breast. Unlike mammography, BSGI is not affected by tissue density. The test is especially useful for patients who have dense breasts, scar tissue, implants, or palpable lesions that cannot be detected using mammography or ultrasound.

Boolbol and her team conducted an IRB-approved review of all patients who underwent BSGI at Beth Israel Medical Center from 2005 to 2008. A total of 82 patients underwent BSGI for newly diagnosed breast cancer. There were five cases of invasive ductal carcinoma, two DCIS, one LCIS, two papillomas, and eight benign biopsies. One patient proceeded directly to mastectomy and an area of DCIS was found, which corresponded to the BSGI.

In the study group, 22 percent of patients had a change in surgical management based on BSGI findings. BSGI detected additional cancer in 9 percent of patients.

"We know that mammography will not detect all breast cancers. This study proves that BSGI is an additional tool to detect breast cancers otherwise missed by standard imaging. Therefore, BSGI plays an important role in the clinical management of patients with known breast cancer," said Dr. Boolbol.

For more information: www.dilon.com

Related Content

FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...
Fujifilm Collaborates With Lunit on AI Pilot Project
News | Artificial Intelligence | December 05, 2018
Fujifilm Medical Systems USA Inc. announced a joint collaboration with Korean-based medical artificial intelligence (AI...
ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...
GE Healthcare Introduces Invenia ABUS 2.0
Technology | Ultrasound Women's Health | December 03, 2018
GE Healthcare recently launched the Invenia automated breast ultrasound (ABUS) 2.0 system in the United States. This...
ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution
Technology | Computer-Aided Detection Software | November 28, 2018
November 28, 2018 — ScreenPoint Medical announced it has received 510(k) clearance from the U.S.
Women Benefit From Mammography Screening Beyond Age 75
News | Mammography | November 26, 2018
Women age 75 years and older should continue to get screening mammograms because of the comparatively high incidence of...
Arterys Demonstrates AI Cloud-Based Medical Image Analysis Solutions at RSNA 2018
News | Computer-Aided Detection Software | November 26, 2018
Medical imaging software company Arterys will demonstrate its wide-ranging suite of artificial intelligence (AI)-...
Novarad Debuts NovaMG-Pro Mammography Software at RSNA 2018
News | Mammography Reporting Software | November 25, 2018
Novarad Corp. announced new mammography software NovaMG-Pro, specifically for multimodality radiologists that read...
Volpara Solutions Showcases Latest VolparaEnterprise Software Tools at RSNA
News | Mammography | November 21, 2018
Volpara Solutions Inc. will showcase its latest artificial intelligence (AI) updates at the 104th Annual Radiological...
QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018
News | Ultrasound Women's Health | November 19, 2018
QView Medical will showcase QVCAD, the first U.S. Food and Drug Administration (FDA)-approved artificial intelligence (...